The present review addresses briefly about the floating drug delivery systems. Oral sustained release gastro-retentive dosage forms (GRDFs) offer many advantages for drugs with absorption from upper parts of gastrointestinal tract and for those acting locally in the stomach, improving the bioavailability of the medication. Floating Drug Delivery Systems (FDDS) is one amongst the GRDFs used to achieve prolonged gastric residence time. GRDDS has become leading methodology in site specific orally administered controlled release drug delivery system. Various drugs, which are unstable in alkaline pH, soluble in acidic pH, having narrow absorption window, site of action specific to stomach can be developed by using this technique. Those gastro retentive systems which depend on liberation of carbon dioxide show poor patient compliance because of flatulence and belching.

Obesity, which is a major cardiovascular risk factor, has now become today. Obesity is most commonly caused by a combination of excessive food energy intake, lack of physical activity, and genetic susceptibility, although a few cases are caused primarily by genes, endocrine disorders, medications or psychiatric illness of emu oil is widely employed in treatment of various diseases and also as a part of various ayurvedic formulations. Emu oil is therapeutically used in methods for lowering cholesterol, triglycerides and low density lipoproteins and increasing high density lipoproteins, preventing and treating allergies; preventing scarring,  treating headaches, preventing nose bleeds, treating and preventing cold and flu symptoms; and relieving discomfort associated with menstruation. In this work is based on how emu oil showing the anti obesity action.

The objective of the present study was to formulate the paroxetine controlled release enteric coated tablet and its in-vitro release kinetics and stability studies. Paroxetine core tablets were prepared by wet granulation process using HPMC K4M and K100M as matrix forming hydrophilic polymers. Instacoat En II (10%) in Isopropyl alcohol (90%) was used as an enteric coating solution. In vitro dissolution study was performed for all the formulations by using Tris buffer as dissolution medium. Different dissolution models were applied to evaluate release mechanisms and its kinetics. The result suggests that F11 formulation showed uniform (zero order) release of drug from the matrix tablet with good correlation value for 12 hours. The effect of paddle RPM in kinetic study was also done for F11 formulation. The stability studies were conducted for F11 at 40^oC ± 2^oC / 75% RH ± 5% for a period of 3 months. No significant differences were observed in the release profile of different batches of each enteric coated paroxetine CR tablet. The similarity and dissimilarity factors for F11 were 0.68 and 95.62 respectively. The best fit with higher correlation was found in the linear regression graph with the Hixon-crowel cube root law for selected formulation F11 and innovator brand. The present study concluded that the formulation F11 was stable and exhibited appreciable controlled release of an enteric coated paroxetine matrix tablet for reproducible and commercial manufacturing.